SCHEMBL24437163

SCHEMBL24437163

Cc1cnccc1NC(=O)c1cn(CC2CC2)c2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 7/20 0.51
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ CNR2 P34972 6/20 0.46
▸ THRB P10828 1/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.44
▸ SLC22A12 Q96S37 1/20 0.44
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ STAT3 P40763 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24437134 0.96 CNR1 (0.54) CNR1MEN1KMT2ACNR2THRB
SCHEMBL24437274 0.88 CNR1 (0.51) CNR1CNR2SLC22A12HTTSMN1; SMN2
SCHEMBL24437144 0.84 CNR1 (0.54) CNR1CNR2SLC22A12
SCHEMBL24437130 0.80 CNR1 (0.50) CNR1
SCHEMBL24437315 0.79 CNR1 (0.45) CNR1CNR2SLC22A12
SCHEMBL24437154 0.79 DYRK1A (0.49) CNR1CNR2HTTSMN1; SMN2L3MBTL1
SCHEMBL24437195 0.79 CNR1 (0.42) CNR1CNR2HTTSMN1; SMN2L3MBTL1
SCHEMBL24437316 0.78 CNR1 (0.53) CNR1MEN1KMT2ACNR2RAB9A
SCHEMBL24437198 0.77 CFD (0.42) CNR1CNR2SLC22A12HTTSMN1; SMN2
SCHEMBL24437128 0.76 CNR1 (0.53) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153735-A1 Orai Channel Inhibitors BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 2022-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153735-A1 Orai Channel Inhibitors ORAI2, ORAI1, ORAI3 CNR1 940/4885MEN1 925/4885KMT2A 3178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback